Cargando…

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

BACKGROUND: Gene expression profiling has consistently identified three molecular subtypes of lung adenocarcinoma that have prognostic implications. To facilitate stratification of patients with this disease into similar molecular subtypes, we developed and validated a simple, mutually exclusive cla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Cordero, Roberto, Ma, Junsheng, Khanna, Abha, Lyons, Genevieve, Rinsurongkawong, Waree, Bassett, Roland, Guo, Ming, Routbort, Mark J., Zhang, Jianjun, Skoulidis, Ferdinandos, Heymach, John, Roarty, Emily B., Tang, Zhenya, Medeiros, L. Jeffrey, Patel, Keyur P., Luthra, Rajyalakshmi, Roy-Chowdhuri, Sinchita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995064/ https://www.ncbi.nlm.nih.gov/pubmed/32005111 http://dx.doi.org/10.1186/s12885-020-6579-z

Ejemplares similares

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges
por: Luthra, Rajyalakshmi, et al.
Publicado: (2015)

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies
por: Chen, Hui, et al.
Publicado: (2015)

Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods
por: Yang, Richard K., et al.
Publicado: (2022)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2023)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer
por: Roy-Chowdhuri, Sinchita
Publicado: (2020)

Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
por: Tang, Zhenya, et al.
Publicado: (2020)

Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression
por: Gu, Jun, et al.
Publicado: (2015)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

SDPS-44 RAPID DETECTION OF MUTATIONS IN CSF-CFTNA WITH THE GENEXUS INTEGRATED SEQUENCER
por: Arjuna, Srividya, et al.
Publicado: (2023)

Editorial: Advances in Molecular Cytopathology
por: Vigliar, Elena, et al.
Publicado: (2022)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

Implant success!!!…..simplified
por: Luthra, Kaushal K.
Publicado: (2009)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS(G12C)-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis
por: Formica, Vincenzo, et al.
Publicado: (2023)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells
por: Ghosh, Sayantani, et al.
Publicado: (2018)

Structure-based classification predicts drug response in EGFR-mutant NSCLC
por: Robichaux, Jacqulyne P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qm2h87ilgc7u5afbin3csbs1u7